N
JSPR icon

Nuveen’s Jasper Therapeutics JSPR Stock Holding History

Nuveen’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-102,268
Closed -$440K – 3333
2025
Q1 		$440K Buy
102,268
+18,851
+23% +$125K ﹤0.01% 2949
2024
Q4 		$1.78M Hold
83,417
– – ﹤0.01% 2433
2024
Q3 		$1.57M Buy
83,417
+62,736
+303% +$1.25M ﹤0.01% 2543
2024
Q2 		$469K Buy
+20,681
New +$496K ﹤0.01% 3018

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Nuveen's JSPR Position: Q2 2025 in Review

Nuveen sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 102,268 shares — an estimated $440K sold.

Nuveen first reported a position in JSPR in Q2 2024 and held it in 4 quarters. The position peaked at $1.78M in Q4 2024. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Nuveen reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 102,268 Jasper Therapeutics shares in Q2 2025, an estimated $440K.
  • Nuveen first reported a position in Jasper Therapeutics in Q2 2024 and held it in 4 quarters.
  • Nuveen's Jasper Therapeutics position peaked at $1.78M in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.